SENXUAN(BJ:830946)2023-02-26 16:00Financial Performance - The company's operating revenue for 2022 is expected to be CNY 623,593,117.91, representing a year-on-year increase of 10.66%[6] - The net profit attributable to shareholders is projected to be CNY 160,544,908.20, reflecting a growth of 22.29% compared to the previous year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses is estimated at CNY 149,943,464.58, which is a 20.32% increase year-on-year[6] - Basic earnings per share are expected to be CNY 0.3761, up 22.29% from the previous year[6] - Total assets at the end of the reporting period are projected to be CNY 1,293,147,896.31, an increase of 7.51% year-on-year[6] - Shareholders' equity attributable to the company is expected to reach CNY 1,086,641,028.20, marking an 8.42% increase compared to the beginning of the year[6] Revenue Growth Drivers - The growth in operating revenue is primarily driven by increased export income from raw material drugs and higher sales of pharmaceutical intermediates[7] - The increase in net profit is attributed to the rise in operating revenue and corresponding gross profit growth[7] Cautionary Notes - The company emphasizes that the financial data presented is preliminary and has not been audited, urging investors to be cautious[8] - The final financial figures will be disclosed in the company's 2022 annual report[8]